ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mirikizumab

Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.

Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.

Drug pageMirikizumab: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 21, 202636 company-led studies, 7 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only356 open or runningphase 4since May 21, 2026Sep 18, 2013Feb 2027phase 1 · NCT07446101
Rubix LS11 open or runningphase 4since Jul 1, 2025Jul 1, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Rubix LS only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named mirikizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, LY3074828
  2. Jul 1, 2025First study: phase 4 study in Crohn DiseaseFirst studyNCT07059130 · 150 planned · United States

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
guselkumabruleJohnson & Johnsonphase 460

Studies

The one study Rubix LS leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07059130Crohn Disease · United States4Not yet recruitingJan 1, 2026150

How it is read

Names in the registry

  • “Mirikizumab”, 24 entries
  • “LY3074828”, 6 entries
  • “Mirikizumab IV”, 3 entries
  • “Mirikizumab SC”, 3 entries
  • “Mirikizumab - SC”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.